Skip to main content
Clinical Trials/NCT07217132
NCT07217132Not yet recruitingNot Applicable

Monitoring the Use of Collagen Dura Membrane - Suturable (DMS) in the Post-market Phase

Collagen Matrix1 site in 1 country54 target enrollmentStarted: December 1, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
54
Locations
1
Primary Endpoint
Rate of Adverse Events Requiring Surgical Intervention

Study Overview

Brief Summary

Monitoring the use of Collagen Dura Membrane - Suturable (DMS) in the post-market phase

Detailed Description

A prospective, post-market clinical study at a maximum of three sites, with an enrollment of 54 subjects. The primary endpoint of the study will be the rate of adverse events related to the Subject Device requiring surgical intervention. The date of each event will be recorded and assessed, including at least one timepoint of 9 months of more post-operatively. Secondary endpoints will include all adverse events (i.e., infection, CSF Leak, and Pseudomeningocele), score of adequacy of product performance, score for product handling at implantation, and score for product adaptability at implantation.

No original patient records or patient identifying information will be disclosed to Collagen Matrix.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with a dural defect requiring repair with a dural substitute
  • Patient is 18 years or older
  • Patient of child-bearing potential is not pregnant or nursing

Exclusion Criteria

  • Patients with a known history of hypersensitivity to bovine derived materials
  • Patients that are non-English speaking
  • Subjects requiring Legally Authorized Representative

Outcomes

Primary Outcomes

Rate of Adverse Events Requiring Surgical Intervention

Time Frame: 9 months

Rate of adverse events related to subject device and requiring surgical intervention.

Secondary Outcomes

  • Rate of Adverse Events(9 months)
  • Score of adequacy of product performance(9 months)
  • Score for Product Handling at Implantation(9 months)
  • Score for Product Adaptability at Implantation(9 months)

Investigators

Sponsor
Collagen Matrix
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials